Travere Therapeutics, Inc. (TVTX)
TVTXNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$51.44
-0.1900 (-0.37%) today
Regular session, Nov 10, 1:58 PM ET
- Market cap
- $4.94bn
- P/E
- –
- EPS, last 4 quarters
- $-1.28
- Dividend yield
- –
- Day range
- $49.79 to $51.65
- 52-week range
- $22.59 to $68.73
- Average volume
- 1.99m
- Previous close
- $51.63
Analysts
12 coveringBuy11 buy, 1 hold, 0 sell
Targets a year out average $72.82, +41.6% from here
Earnings
next estimate $0.3300Next report
Dec 2025
0.0%
Mar 2026
-30.0%
Jun 2026
-164.3%
Sep 2026
-120.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $129.69m | $127.20m | $169.58m | $224.56m |
| Gross profit | $127.14m | $125.25m | $167.41m | $221.69m |
| Operating income | -$32.43m | -$36.91m | $3.95m | -$68.11m |
| Net income | $2.73m | -$37.10m | -$34.80m | -$52.34m |
Last four quarters: revenue $651.03m, margin -18.7%, free cash flow –
News
8 latest- Travere (TVTX) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 2, 2026
- What Travere Therapeutics (TVTX) Said on Its Q3 Earnings CallMarketBeat · Nov 2, 2026
- Here's What Key Metrics Tell Us About Travere (TVTX) Q3 EarningsZacks · Nov 2, 2026
- Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 2, 2026
- Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue EstimatesZacks · Oct 28, 2026
- Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?Zacks · Oct 28, 2026
- AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA NephropathyZacks · Oct 22, 2026
- Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to DeclineZacks · Oct 22, 2026
The company
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent - that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- travere.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.